Major issues in translational medicine

Conflict of interest

Jacek Z. Kubiak is the Editor-in-Chief of this journal. The author declares that he has no known competing financial interests or personal relationships that could have influenced the work reported in this paper.

References

[1] Loh JS, Low CY, Low WP, et al. Traversing the Valley of Death for nanotechnology-based natural products: Strategies and insights from pharmaceutical stakeholders. Drug Deliv Transl Res. 2025; 15(11):4126-4140. doi: 10.1007/s13346-025-01923-8

[2] Failli V, Strittmatter SM, Schwab ME, et al. Crossing the valley of death in spinal cord injury: Learning from successful translators. Neurotrauma Rep. 2025; 6(1):298-310. doi: 10.1089/neur.2025.0029

[3] Zhu H, Yu J, Luo J, Cai Z, Li L, Zheng Q. Development of a cross-species model to predict clinical outcomes based on efficacy in mouse models of non-alcoholic fatty liver disease. Clin Res Hepatol Gastroenterol. 2025; 49(9):102702. doi: 10.1016/j.clinre.2025.102702

[4] Barroca NCB, Della Santa G, Suchecki D, García- Cairasco N, Umeoka EHL. Challenges in the use of animal models and perspectives for a translational view of stress and psychopathologies. Neurosci Biobehav Rev. 2022; 140:104771. doi: 10.1016/j.neubiorev.2022.104771

[5] Ostrand-Rosenberg S. Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr Opin Immunol. 2004; 16(2):143-50. doi: 10.1016/j.coi.2004.01.003

[6] Ferreira RS Jr., Mantovani CK, Ferreira ASSBS, et al. Translational science at the undergraduate level: Awakening talents to overcome the valley of death - case report. J Venom Anim Toxins Incl Trop Dis. 2025; 31:e20250005. doi: 10.1590/1678-9199-jvatitd-2025-0005

[7] Mir A, Zhu A, Lau R, et al. Applications, limitations, and considerations of clinical trials in a dish. Bioengineering (Basel). 2024; 11(11):1096. doi: 10.3390/bioengineering11111096